News

Scynexis entered into an exclusive agreement with GSK for Brexafemme (ibrexafungerp), a U.S. FDA approved antifungal for the treatment of vaginal yeast infections and vulvovaginal candidiasis (VVC). Under the terms of the global license agreement, GSK will pay Scynexis $90 million upfront, plus...

Together with Munich’s Ludwig Maximilian University (LMU) and the Humboldt University of Berlin (HU Berlin), Wacker Chemie AG and CordenPharma International GmbH have launched a project to accelerate the development of RNA-based drugs. The aim is to develop a...

Drug manufacturers are not able to provide Europeans with the required information to gauge the benefits and defects of oncology medicines. This is as per the findings published in The BMJ, which demonstrate that the patient information leaflets consistently...

Griffith University, based in Australia, has gone on to conduct a world-first study when it comes to cell transplantation so as to repair nervous system injuries and has thus received a tremendous boost of a $5.4 million fund extension...

A £277 million joint government-industry finance package will assist four UK life sciences companies in moving forward with life sciences manufacturing initiatives. The Life Sciences Innovative Manufacturing Fund (LSIMF) has just released its first round of funding. Government financing of £17 million...

Crinetics Pharmaceuticals, a pharmaceutical company that develops therapies for rare endocrine diseases, and Quotient Sciences, a drug development and manufacturing accelerator, have announced a partnership to support Crinetics’ CRN04894 pediatric program. The partnership will utilize Quotient Sciences’ unique Translational...

Intrathecal (IT), intravenous (IV), and Nivolumab (anti-PD-1) immunotherapy were found to be safe and prolong life in a subset of melanoma individuals with leptomeningeal illness (LMD). The interim evaluations of the innovative delivery strategy were presented in the first-in-human Phase...